{"brief_title": "ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Na\u00efve HIV-Infected Subjects", "brief_summary": "To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Stavudine", "description": "40 mg every 12 hours", "arm_group_label": "2", "other_name": "Kaletra", "criteria": "Inclusion Criteria - HIV-1 positive - antiretroviral-adult males - non-pregnant - non-lactating females at least 18-years old with plasma HIV-1 RNA > 5000 copies/mL, who were not acutely ill Exclusion Criteria - History of: - prior antiretroviral therapy - significant drug hypersensitivity - psychiatric illness that precludes compliance - an active substance abuser - positive test results for drug abuse - abnormal lab test results (hemoglobin, absolute neutrophil count, platelet count, SGPT/AST or SGPT/ALT, creatinine, fasting triglycerides, significant abnormal ECG results - pregnancy or lactating female - received another investigational drug within 28 days of study initiation - unlikely to comply or unsuitable candidate in the opinion of the investigator", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00004578.xml"}